Amgen, Inc. vs American Well Corp — how do they compare? Amgen, Inc. trades at $415.25 (market cap $224.14B), while American Well Corp trades at $12.95 (market cap $220.94M). The key difference: Amgen, Inc. is far larger — about 1014.5× American Well Corp's market cap, and Amgen, Inc. pays a 2.43% dividend while American Well Corp pays none. Which is the better fit depends on your goals.
| AMGN | AMWL | |
|---|---|---|
Market Cap | $224.14B | $220.94M |
Sector | Health | Health |
52-Week High | $417.20 | $13.58 |
52-Week Low | $271.18 | $3.78 |
Enterprise Value | $267.45B | $27.98M |
Dividend Yield | 2.43% | — |
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
AMWL trades at $13.58, up 0.44% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $52 million, beating estimates, and continues to narrow losses. Recent news includes a key executive joining Amazon's healthcare unit, potentially opening partnership opportunities.
The outlook is cautiously optimistic as AMWL progresses toward cash-flow breakeven, but persistent net losses and negative margins pose risks. Analyst consensus is mixed, with 33% buy ratings, reflecting uncertainty around profitability timelines amid competitive pressures.
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →American Well Corp is a telehealth company enabling digital delivery of care for its customers. Its platform, Amwell, digital care delivery solution that equips health systems, health plans, government, and innovator clients with the tools to enable new models of care for their patients and members enabling care delivery across the full healthcare continuum - from primary and urgent care in the home to high acuity specialty consults, such as telestroke and telepsychiatry, in the hospital. It provides both on-demand and scheduled consultations. Its Health Plan Programs include Virtual Primary Care, Musculoskeletal Care, Dermatology Care, and Chronic Care among others and its Health System Modules include Acute Behavioral Health, ED Triage, Pediatrics and Telestroke among others.
Read more on AMWL →